文献标题:AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
文献出处:Sci Transl Med 4:(120): 120ra15
期刊影响因子:3.511
PMID:暂无
新华网华盛顿2月8日电(记者任海军)美国研究人员8日在《科学·转化医学》杂志上报告说,3名遗传性眼病患者接受基因疗法治疗后,视力显著提高且无排异反应等不良情况发生。这为利用基因疗法治疗其他视网膜病变带来了希望。
这3名患者患有罕见眼疾—莱贝尔先天黑内障。这种病通常在患者年幼时发作,患者视网膜细胞的一种基因发生变异,致使视力严重下降、眼球活动异常。到二三十岁时,患者可能完全失明。宾夕法尼亚大学和费城儿童医院研究人员利用腺病毒载体将修正基因RPE65植入患者眼球内,病毒将感染视网膜患病细胞,将变异基因“重写”为正常基因。
出于谨慎,研究人员最初仅为每名患者视力较差的一只眼进行了治疗,经过几年的观察确认安全性和有效性后,研究人员又利用同样方法对患者另一只眼进行了治疗。治疗后患者能辨认出人脸,而这是接受治疗前做不到的,并且患者对弱光的敏感度显著提高。
研究摘要:
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Demonstration of safe and stable reversal of blindness after a single unilateral subretinal injection of a recombinant adeno-associated virus (AAV) carrying the RPE65 gene (AAV2-hRPE65v2) prompted us to determine whether it was possible to obtain additional benefit through a second administration of the AAV vector to the contralateral eye. Readministration of vector to the second eye was carried out in three adults with Leber congenital amaurosis due to mutations in the RPE65 gene 1.7 to 3.3 years after they had received their initial subretinal injection of AAV2-hRPE65v2. Results (through 6 months) including evaluations of immune response, retinal and visual function testing, and functional magnetic resonance imaging indicate that readministration is both safe and efficacious after previous exposure to AAV2-hRPE65v2. |